A new study using machine learning is the first of its kind to comprehensively characterize how proteoglycans play a role in breast cancer prognosis and tumor aggressiveness.

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors.

A new gene-editing method enables researchers to more easily determine whether a patient has inherited an increased risk of developing cancer - before any symptoms appear. Researchers at Rigshospitalet in Copenhagen have tested the method in a hospital setting and believe it has the potential to save lives worldwide.

Researchers from the University of São Paulo have identified a molecule in arachnid venom that acts similarly to a commonly used chemotherapy drug for treating the disease; preliminary results of the study were presented at FAPESP Week France.